Details:
Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.
Lead Product(s): KIT2014
Therapeutic Area: Genetic Disease Product Name: KIT2014
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Claris Ventures
Deal Size: $18.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 16, 2022